trending Market Intelligence /marketintelligence/en/news-insights/trending/UNl1f3Ap-TcRllFCB2h8oA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

OptimizeRx prices share at $10 each for public offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


OptimizeRx prices share at $10 each for public offering

OptimizeRx Corp. priced its share at $10 each for a public offering initiated by its shareholder WPP Luxembourg Gamma Three S.À R.L., a unit of WPP PLC.

WPP Luxembourg Gamma Three SÀRL plans to sell its entire holding of 2,103,702 OptimizeRx common shares representing 17.51% of the company as of June 1, according to the most recent S&P Global Market Intelligence data. OptimizeRx will give underwriters a 30-day option to buy as much as an additional 315,555 shares at the public offering price less the underwriting discount and commissions.

OptimizeRx will not receive any proceeds from the offering. However, if the underwriters exercise the option to purchase up to 315,555 additional shares in full, OptimizeRx will receive net proceeds of approximately $2.9 million. OptimizeRx plans to use the proceeds for working capital and other general corporate purposes.

The offering is expected to be complete on or around Dec. 20, subject to customary closing conditions.

William Blair & Co. and B. Riley FBR Inc. are the joint book-running managers for the offering. Roth Capital Partners and Lake Street Capital Markets are the financial advisers for the offering.